UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 ___________________________ SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Char ...

Financial Data and Key Metrics Changes - Revenue for Q4 2022 was $65,000, compared to $26,000 for Q4 2021, indicating growth in test volumes [52] - Total operating expenses for Q4 were $10.5 million, down from $12.6 million year-over-year [53] - Net loss for Q4 2022 was $9.7 million, reduced from $12.5 million in Q4 2021 [53] - Cash, cash equivalents, and available-for-sale securities as of December 31, 2022, were approximately $104 million [54] Business Line Data and Key Metrics Changes - The company reported a six-fold increase in test volumes for Q4 2022 compared to Q4 2021, and an eleven-fold increase for the total units in 2022 versus 2021 [34] - The focus remains on early adopter systems, including integrated delivery networks and physician practice groups, to drive adoption of the PreTRM technology [35] Market Data and Key Metrics Changes - The company is experiencing keen interest from payers following the announcement of the AVERT study results, although full payer adoption is contingent on peer-reviewed publications [60] - Early adopter payers are willing to move forward based on preliminary data, while others prefer to wait for final results from the PRIME study [68] Company Strategy and Development Direction - The company aims to accelerate adoption of the PreTRM technology through the publication of compelling new data [35] - A successful validation of an ambient blood collection and transport system for PreTRM testing was launched to reduce costs and increase test volume [37] - The company is focused on building relationships with early adopter systems to implement the PreTRM testing effectively [71] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the interim look of the PRIME study, expected to occur by the end of the year, which could influence payer decisions [69] - The company anticipates that positive results from the AVERT study and other upcoming publications will support revenue growth [55] Other Important Information - The AVERT PRETERM TRIAL showed statistically significant improvements in neonatal health outcomes, which management believes will bolster the PreTRM test-and-treat strategy [39] - The PRIME study has surpassed 2,800 enrolled patients, meeting the requirement for an interim analysis [39] Q&A Session Summary Question: Potential impact of AVERT interim readout on payer conversations - Management clarified that the AVERT readout was not an interim look but final analysis results, which have generated keen interest among payers [60] Question: Expense management and scaling the salesforce in 2023 - The focus is on early adopter systems, with no significant increase in expenses expected for 2023 [63] Question: Revenue expectations for 2023 - Management indicated that revenues are expected to be less than $1 million for 2023, reflecting the early stage of commercialization [54]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-K ___________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 ___________________________ SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) ...

Sera Prognostics, Inc. (NASDAQ:SERA) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - President and CEO Jay Moyes - CFO Conference Call Participants Patrick Donnelly - Citi Andrew Brackmann - William Blair Tom Stevens - Cowen Operator Good afternoon, and welcome to the Sera Prognostics conference call to review Third Quarter Fiscal Year 2022 results. At this time, all participants are in a listen-only mode. We will be f ...

Sera Prognostics, Inc. (NASDAQ:SERA) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Greg Critchfield - Chairman, President & Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call Participants Dustin Scaringe - William Blair Dan Brennan - Cowen Operator Good afternoon and welcome to the Sera Prognostics’ Conference Call to review Second Quarter Fiscal Year 2022 Results. At this time, all participants are in a listen-onl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 ___________________________ SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Chart ...

Sera Prognostics, Inc. (NASDAQ:SERA) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Greg Critchfield - Chairman, President and Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dustin Scaringe - Blair Anita Dushyanth - Berenberg Operator Good afternoon and welcome to the Sera Prognostics’ Conference Call to review First Quarter Fiscal Year 2022 Results. At this time, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 ___________________________ SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Char ...

Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2021 Earnings Conference Call March 29, 2022 5:00 PM ET Company Participants Peter DeNardo - IR Gregory Critchfield - Chairman, President, and CEO Jay Moyes - CFO Conference Call Participants Patrick Donnelly - Citi Dustin Scaringe - William Blair Kevin DeGeeter - Oppenheimer Operator Good afternoon and welcome to the Sera Prognostics' Conference Call to Review the Fourth Quarter and Fiscal Year of 2021 Results. At this time, all participants are in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-K ___________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 ___________________________ SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) ...